You are here
- Home
Total number of clinical trials
- collapse A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
- collapse Evaluation of sub-syndromal symptoms after acute depressive episode in bipolar disorder.
- collapse A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)
- collapse Drug utilization and safety events among children using esomeprazole, other proton pump inhibitors or H2-receptor antagonists
- collapse A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients.
- collapse Observational retrospective Study to Describe the Management of Advanced or Metastatic EGFR Mutated Non-small Cell Lung Cancer Patients in Spain.
- collapse A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults
- collapse A diagnostic study to determine the prevalence of EGFR mutations in Asian and Russian patients with advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma histologies
- collapse Tolerability,Pharmacokinetics&Preliminary Antitumour Activity of Ascending Doses of AZD9291 in Patients With Advanced Non Small Cell LungCancer Who Have Progressed Following Prior Therapy With an Epidermal Growth FactorReceptorTyrosineKinaseInhibatoragent
- collapse A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer (ACT-FASTER:)
